The improved revenue result was driven primarily by sales increasing in Australia, due to the launch of Oventus’ new lightweight nylon O2 Vent Optima devices for the treatment of OSA (obstructive sleep apnoea) and snoring.
Oventus managing director Dr Chris Hart will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.
Dr Chris Hart
New product to improve airflow and airway stability
O2 Vent Optima is the first of two new products coming to market in 2019.
The second product is a valve that integrates with select O2 Vent devices to naturally improve airflow and airway stability.
The valve is called the ExVent and in combination with Oventus’ Airway Technology, has been clinically proven to dramatically increase the success rates over traditional mouthguard devices for sleep apnoea sufferers.
Highly anticipated product
Following the Australian release of ExVent, the product will be launched in North America and Europe, subject to regulatory approval.
This new treatment modality is highly anticipated by the sleep community and, along with O2 Vent Optima is potentially transformational for the company.
Register for the CEO Sessions today